RecruitingPhase 2NCT05421416

Loratadine for the Prevention of G-CSF-related Bone Pain

Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization

Sponsor

AHS Cancer Control Alberta

Enrollment

78 participants

Start Date

Nov 28, 2024

Study Type

INTERVENTIONAL

Conditions

Stem Cell Transplant Complications

Summary

The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Loratadine and a drug called Placebo for people with stem cell transplant complications. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.